195 related articles for article (PubMed ID: 16715936)
1. [Secondary progressive multiple sclerosis in childhood--interferon beta 1b treatment].
Higurashi N; Hamano S; Eto Y
No To Hattatsu; 2006 May; 38(3):209-13. PubMed ID: 16715936
[TBL] [Abstract][Full Text] [Related]
2. Spotlight on Interferon-beta-1b in relapsing-remitting and secondary progressive multiple sclerosis.
McCormack PL; Scott LJ
BioDrugs; 2004; 18(5):343-7. PubMed ID: 15377176
[TBL] [Abstract][Full Text] [Related]
3. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.
Montalban X; Sastre-Garriga J; Tintoré M; Brieva L; Aymerich FX; Río J; Porcel J; Borràs C; Nos C; Rovira A
Mult Scler; 2009 Oct; 15(10):1195-205. PubMed ID: 19797261
[TBL] [Abstract][Full Text] [Related]
4. Interferon beta for secondary progressive multiple sclerosis.
La Mantia L; Vacchi L; Di Pietrantonj C; Ebers G; Rovaris M; Fredrikson S; Filippini G
Cochrane Database Syst Rev; 2012 Jan; 1():CD005181. PubMed ID: 22258960
[TBL] [Abstract][Full Text] [Related]
5. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.
Panitch H; Miller A; Paty D; Weinshenker B;
Neurology; 2004 Nov; 63(10):1788-95. PubMed ID: 15557491
[TBL] [Abstract][Full Text] [Related]
6. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.
Lancet; 1998 Nov; 352(9139):1491-7. PubMed ID: 9820296
[TBL] [Abstract][Full Text] [Related]
7. Interferon-beta 1b in the treatment of multiple sclerosis.
Río J; Montalban X
Expert Opin Pharmacother; 2005 Dec; 6(16):2877-86. PubMed ID: 16318438
[TBL] [Abstract][Full Text] [Related]
8. [Limited effect of interferon-beta for the treatment of secondary progressive multiple sclerosis].
Schreiber K; Voldsgaard A; Sørensen PS
Ugeskr Laeger; 2013 May; 175(19):1342-4. PubMed ID: 23663372
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of a 'refrigeration-free' formulation of interferon beta-1b--results of a double-blind, multicentre, comparative study in patients with relapsing-remitting or secondary progressive multiple sclerosis.
Baum K;
J Int Med Res; 2006; 34(1):1-12. PubMed ID: 16604818
[TBL] [Abstract][Full Text] [Related]
10. Interferon β for secondary progressive multiple sclerosis: a systematic review.
La Mantia L; Vacchi L; Rovaris M; Di Pietrantonj C; Ebers G; Fredrikson S; Filippini G
J Neurol Neurosurg Psychiatry; 2013 Apr; 84(4):420-6. PubMed ID: 22952326
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study.
Fernández O; Guerrero M; Mayorga C; Muñoz L; Leán A; Luque G; Hervás M; Fernández V; Capdevila A; de Ramón E
J Neurol; 2002 Aug; 249(8):1058-62. PubMed ID: 12195454
[TBL] [Abstract][Full Text] [Related]
12. [Interferon beta-1b for treatment of secondary chronic progressive multiple sclerosis].
Zimmermann C; Walther EU; Goebels N; Lienert C; Kappos L; Hartung HP; Hohlfeld R
Nervenarzt; 1999 Aug; 70(8):759-63. PubMed ID: 10483579
[TBL] [Abstract][Full Text] [Related]
13. Interferon beta-1b (betaseron/betaferon) is well tolerated at a dose of 500 microg: interferon dose escalation assessment of safety (IDEAS).
Gottesman MH; Friedman-Urevich S
Mult Scler; 2006 Jun; 12(3):271-80. PubMed ID: 16764339
[TBL] [Abstract][Full Text] [Related]
14. The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS.
Inglese M; van Waesberghe JH; Rovaris M; Beckmann K; Barkhof F; Hahn D; Kappos L; Miller DH; Polman C; Pozzilli C; Thompson AJ; Yousry TA; Wagner K; Comi G; Filippi M
Neurology; 2003 Mar; 60(5):853-60. PubMed ID: 12629246
[TBL] [Abstract][Full Text] [Related]
15. A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis.
Kuhle J; Hardmeier M; Disanto G; Gugleta K; Ecsedi M; Lienert C; Amato MP; Baum K; Buttmann M; Bayas A; Brassat D; Brochet B; Confavreux C; Edan G; Färkkilä M; Fredrikson S; Frontoni M; D'Hooghe M; Hutchinson M; De Keyser J; Kieseier BC; Kümpfel T; Rio J; Polman C; Roullet E; Stolz C; Vass K; Wandinger KP; Kappos L;
Mult Scler; 2016 Apr; 22(4):533-43. PubMed ID: 26362898
[TBL] [Abstract][Full Text] [Related]
16. T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment.
Barkhof F; van Waesberghe JH; Filippi M; Yousry T; Miller DH; Hahn D; Thompson AJ; Kappos L; Brex P; Pozzilli C; Polman CH;
Brain; 2001 Jul; 124(Pt 7):1396-402. PubMed ID: 11408334
[TBL] [Abstract][Full Text] [Related]
17. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials.
Kappos L; Weinshenker B; Pozzilli C; Thompson AJ; Dahlke F; Beckmann K; Polman C; McFarland H; ;
Neurology; 2004 Nov; 63(10):1779-87. PubMed ID: 15557490
[TBL] [Abstract][Full Text] [Related]
18. A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis.
Touchette DR; Durgin TL; Wanke LA; Goodkin DE
Clin Ther; 2003 Feb; 25(2):611-34. PubMed ID: 12749517
[TBL] [Abstract][Full Text] [Related]
19. [Autoimmune functional disorders of the thyroid during interferon-beta-1b treatment in patients with multiple sclerosis. Case report and literature review].
Lange-Asschenfeldt C; Boor S; Kahaly GJ; Thömke F
Nervenarzt; 2004 Jun; 75(6):589-94. PubMed ID: 15257382
[TBL] [Abstract][Full Text] [Related]
20. Etretinate augments interferon beta-1b effects on suppressor cells in multiple sclerosis.
Qu ZX; Pliskin N; Jensen MW; White D; Arnason BG
Arch Neurol; 2001 Jan; 58(1):87-90. PubMed ID: 11176940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
